Tara K. Gregory, MD, Colorado Blood Cancer Institute, Denver, Colorado, discusses CAR T-cell therapy for multiple myeloma. Dr Gregory reviews steps involved in CAR T-cell therapy, potential outcomes and risks, the impact on quality of life, and which patients may be good candidates for CAR T-cell therapy.
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Doris Hansen, MD, Moffitt Cancer Center, Tampa, Florida, discusses an analysis of pretreatment biomarkers associated with toxicity and durable response related to idecabtagene vicleucel therapy for patients with…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of…
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
